This analysis specifically targeted over 100 proteins implicated in modulating the tumor immune microenvironment, aiming to identify pivotal molecular players that could potentiate the efficacy of existing and novel therapeutic agents.[3] Our analysis revealed elevated expressions of multiple tumor immune response‐related proteins, including B7‐H4 (VTCN1), PD‐L1 (CD274), and Galectin9 (LGLAS9), in the TNBC compared to other subtypes (Figure1A). The gene discussed is VTCN1; the disease is neoplasm.